血清人表皮生长因子受体2水平在乳腺肿瘤诊断与治疗中的应用

The application of serum level of HER2 in the diagnosis and treatment of breast cancer

目的探讨患者血清人表皮生长因子受体2(HER2)水平的检测在乳腺肿瘤诊断与治疗中的临床意义。方法运用课题组前期研制的用于检测人血清中HER2含量的ELISA试剂盒对参与者血清样本进行检测。结果乳腺包块患者、早期乳腺癌患者以及转移性乳腺癌患者血清中的HER2水平明显高于健康对照组(P<0.05)。对于转移性乳腺癌患者,术后未用曲妥珠单抗治疗的患者血清HER2水平明显高于术后使用曲妥珠单抗治疗的患者。病理结果显示HER2阳性且术后化疗的患者行多次血清检测,发现血清HER2值与临床肿瘤标志物癌胚抗原水平之间呈现正相关(P<0.05)。结论检测血清HER2水平对乳腺疾病临床诊断有较好的价值,同时可以用于评价曲妥珠单抗对乳腺肿瘤的治疗效果。

Objective To explore the clinical significance of serum HER2 level in the diagnosis and treatment of breast cancer.Methods The specific ELISA kit developed by our research group earlier was used to measure the serum HER2 levels.All the results were analyzed by corresponding statistical methods.Results The serum HER2 level in patients with breast lump,early-stage breast cancer and metastatic breast cancer was significantly higher than those in healthy control group(P<0.05).In metastatic breast cancer patients,the serum level of HER2 in these without Herceptin treatment was significantly higher than those with Herceptin treatment after surgery.Additionally,in HER2-positive with Herceptin treatment patients,a positive correlation between serum HER2 levels and the level of tumor marker CEA was observed.Conclusion The serum level of HER2 may provide clinical significance in the diagnosis of breast lumps and cancer,moreover serum HER2 monitoring could be used to evaluate the therapeutic effect of Herceptin in the patients with breast cancer.